Status:
UNKNOWN
Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Postprandial Hypoglycemia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Roux-en-Y gastric bypass (RYGB) is the most common surgical procedure for morbid obesity. However, it can present serious late complications, like postprandial hyperinsulinemic hypoglycemia (PHH). Rec...
Detailed Description
A prospective opened, placebo uncontrolled, pilot interventional study is performed at the Morbid Obesity Unit of the Vall Hebron University Hospital, including patients that have previously undergone...
Eligibility Criteria
Inclusion
- Patients diagnosed with PHH following Roux-en-Y-gastric by-pass, by means of 100g Glucose OGTT. Plasma glucose \<50mg/dl.
- Patients that during any time of the OGTT present at least one value of plasma glucose \>200mg/dl, besides hypoglycemia
Exclusion
- Patients unwilling to take canagliflozin 300mg
- Patients that present with PHH following other bariatric surgery techniques
Key Trial Info
Start Date :
January 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04720859
Start Date
January 5 2018
End Date
December 31 2022
Last Update
January 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andreea Ciudin
Barcelona, Spain, 08035